- Home
- / IMUNON
IMUNON
Stock Price
$1
2024-10-29
Market Capitalization
$13.8 M
2024-10-29
Revenue
$500 K
FY, 2022
IMUNON Summary
Company Summary
- Overview
- IMUNON (formerly known as Celsion) is a biotechnology company developing DNA-based immunotherapies, vaccines, and directed chemotherapies. It provides TheraPlas, a platform for the development of immunotherapies and anti-cancer nucleic acid-based therapies, and PLACCINE, a platform for the development of nucleic acid vaccines for infectious diseases and cancer.
- Type
- Public
- Status
- Active
- Founded
- 1982
- HQ
- Trenton, NJ, US | view all locations
- Website
- https://imunon.com/
- Cybersecurity rating
Table of Contents
Key People
Augustine Chow, Director
Nicholas Borys, Vice President and Chief Medical Officer
Jeffrey W. Church, Senior Vice President, Chief Financial Officer and Corporate Secretary
LocationsView all
1 location detected
Trenton, NJ HQ
United States
997 Lenox Dr #100
IMUNON Financials
Summary Financials
- Cash (Q1, 2026)
- $4.8M
- EBIT (Q1, 2026)
- ($4.3M)
- Enterprise value
- $9.9M